Emyria has received firm bids of $2.525M from new and existing investors, including a significant cornerstone subscription from Chairman Greg Hutchinson. These funds will support the expansion of mental health treatment services at Emyria's Empax Centre, including programs for treatment-resistant depression and PTSD. With a focus on addressing unmet mental health needs affecting over 1,000,000 Australians, Emyria is uniquely positioned to scale its care model and improve patient access and well-being.

The Placement, comprising the issue of approximately 72,142,858 shares at $0.035 each, represents a discount to the last traded price and will be issued in two tranches. Chairman Hutchinson's investment of $1,000,000 demonstrates confidence in Emyria's mission. Settlement of the first tranche is expected in December 2024, with the second subject to shareholder approval in February 2025.

Emyria's integrated model of direct clinical services and drug development aims to deliver innovative treatments for mental health and neurological conditions, backed by robust Real-World Data. Investors are encouraged to engage with Emyria through the Interactive Investor Hub to ask questions and stay informed about the Company's progress.

For more information or investment opportunities, investors can contact Managing Director Michael Winlo, Media Contact Haley Chartres, or Corporate Advisor Sufian Ahmad. Emyria is committed to advancing mental health solutions and welcomes inquiries from interested parties.